home > news > detailed info

Transpire Bio Announces Second Agreement With Recipharm for the Development of Two Additional Inhaled Medicines

Recipharm Pharmaceutical Development AB

Transpire Bio announces second agreement with Recipharm for the development of two additional inhaled medicines

September 29 2022 – Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a second definitive agreement with Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).

TRB-3 and TRB-4, marking the rapid progression of the Transpire Bio pipeline, are inhaled products being developed for advanced markets. With a focus on streamlining the development process, these two new products will expand Transpire Bio’s reach as it looks to bring new, complex inhaled medicines to market.

“We are continuing our relentless pursuit of improving access to important, life-saving inhaled therapies, while methodically building capabilities for new inhaled therapies which will help address areas of significant unmet medical need”, said Dr. Xian-Ming Zeng, CEO of Transpire Bio. “With TRB-3 and TRB-4 we are demonstrating our ability to rapidly progress our pipeline in an effort to meet patient needs as quickly as possible. We are very excited to again be working with Recipharm to advance these important medicines.”

Jean-Francois Hilaire, Executive Committee Member, Head of Business Unit Advanced Delivery Systems added: “TRB-3 and TRB-4 are exciting developments for the treatment of two increasingly common chronic respiratory conditions. Recipharm is delighted to collaborate with Transpire Bio again and we will continue to share our extensive experience and expertise in developing and commercializing inhalation products to help bring these new inhaled medicines to market.”

According to statistics from the World Health Organization, asthma affected approximately 262 million people in 2019, and accounted for approximately 455,000 deaths. COPD was the third-leading cause of death in 2019, with approximately 3.2 million lives lost.

It was announced earlier this year that Transpire Bio had entered into an agreement with Recipharm for the development and commercialization of TRB-1 and TRB-2.
Print this page
Send to a friend
News and Press Releases


More info >>

White Papers

Maximize the ROI of Your Post-Approval Research


Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement